FDA AdCom backs Gilead's move to expand Descovy label — but stops short of endorsing broad PrEP use

Gilead is one step closer to unlocking a potentially blockbuster new use of its two-drug HIV regimen Descovy — though probably not all of it.

In a meeting late Wednesday, the FDA’s Antimicrobial Drugs Advisory Committee voted 16 to 2 endorsing Descovy as a pre-exposure prophylaxis, or PrEP, in men and transgender women who have sex with men.